JULIETA ALMAZAN: Open Payments
NPI 1588289532 · TYLER, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,257 in 40 payments from 10 companies in 2025. Trend: 2023 $928 · 2024 $1,112 · 2025 $1,257
Food & beverage: $1,257
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $406 |
| Janssen Biotech, Inc. | 2 | $205 |
| GENZYME CORPORATION | 6 | $201 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $119 |
| Ardelyx, Inc. | 1 | $106 |
| Novo Nordisk Inc | 1 | $46 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $20 |
| Mirum Pharmaceuticals, Inc. | 1 | $14 |
| QOL Medical, LLC | 1 | $14 |
Products named: TREMFYA, DUPIXENT, LINZESS, ZENPEP, ENTYVIO, IBSRELA, RINVOQ, SKYRIZI.
Industry payments across TX — which companies pay providers there.
